Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has strengthened its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with core products like Darbeshou (Sintilimab injection) showing steady growth [2] - The company has successfully ventured into the chronic disease commercialization field, leveraging unmet needs and strong product competitiveness to drive growth, with key products like Xin'ermei (Masitide injection) and Xinbile (Torecilizumab injection) becoming significant revenue contributors [2] Group 2 - The company's global innovation strategy continues to make breakthroughs, focusing on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC) in oncology, as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its ongoing clinical development and strategic advantages in flexible layout and efficient execution [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） 內幕消息公告－2025年全年及第四季度產品收入實現強勁增長 本公告由信達生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部作出。 （股份代號：1801） 於2025年全年，本公司實現總產品收入約人民幣119億元，同比保持約45%的強 勁增長態勢。值得說明的是，於2025年第四季度，因六款新藥首次納入2026年國 家醫保目錄，本公司就按原價格分銷至渠道的產品，計提了相應金額的一次性庫 存補差。前述情況下，於2025年第四季度，本公司實現總產品收入約人民幣33億 元，同比增長超60%以上，依舊延續強勁增長勢頭。 2025年是本公司產品收入首次突破百億人民幣的里程碑之年，標誌着本公司「雙 輪驅動 ...

香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股，每股作价83.829港 元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比例为5%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股， 每股作价83.829港元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比 例为5%。 ...

Core Viewpoint - The stock of Innovent Biologics (01801) rose nearly 3% following the announcement that its drug IBI3003 received Fast Track Designation from the FDA for treating relapsed or refractory multiple myeloma [1] Group 1: Company Developments - Innovent Biologics' IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3, which is currently undergoing Phase I/II clinical trials in China, Australia, and the United States [1] - The FDA's Fast Track Designation is aimed at patients who have undergone at least four lines of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody [1] Group 2: Market Reaction - As of the report, Innovent Biologics' stock price increased by 2.2%, reaching 83.6 HKD, with a trading volume of 204 million HKD [1]

Core Viewpoint - Cinda Biologics (01801) shares rose nearly 3%, currently up 2.2% at HKD 83.6, with a trading volume of HKD 204 million [1] Group 1: Company Developments - Cinda Biologics announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 received Fast Track Designation from the U.S. FDA on January 27, 2026 [1] - The intended indication for IBI3003 is for relapsed or refractory multiple myeloma (R/R MM) patients who have undergone at least four lines of treatment, including a proteasome inhibitor (Pl), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody [1] - IBI3003 is developed using Cinda Biologics' proprietary Sanbody platform and is currently undergoing Phase I/II clinical trials in China, Australia, and soon in the U.S. to explore its efficacy and safety in R/R MM [1]

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 1.345 million shares at an average price of HKD 90.0345 per share, totaling approximately HKD 121 million [1] - Following the acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87,775,465 shares, increasing its ownership percentage from 4.98% to 5.06% [1]

Core Viewpoint - UBS report indicates that Innovent Biologics is confident in its sales performance in the Chinese market, driven by oncology and cardiovascular products, and aims to achieve a product sales target of 20 billion yuan by 2027 [1] Group 1 - Innovent Biologics is focusing on the sales performance of its products in the Chinese market and the development progress of the key candidate drug IBI363 (PD-1/IL-2a) in collaboration with Takeda Pharmaceutical [1] - The company maintains its target of achieving 20 billion yuan in product sales by 2027 [1] - Innovent aims to advance five candidate drugs into global multi-center randomized controlled trial stages before 2030 [1] Group 2 - UBS sets a target price of HKD 137.4 for Innovent Biologics and maintains a "Buy" rating [1]

责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，1月2日，小摩增持信达生物（01801）317.3036万股，每股作价78.4477港 元，总金额约为2.49亿港元。增持后最新持股数目约为8895.73万股，最新持股比例为5.16%。 香港联交所最新资料显示，1月2日，小摩增持信达生物（01801）317.3036万股，每股作价78.4477港 元，总金额约为2.49亿港元。增持后最新持股数目约为8895.73万股，最新持股比例为5.16%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

| 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 09/12/2025 - 09/01/2026 | | 豪格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的 | | --- | --- | --- | --- | --- | | | 分野信 | | | ( 謂參閱工処 註解 ) 月 反宗 催版 ( | | | | | | 份自分厨 | | | | | | 9/0 | | CS20260107E00514 | JPMorgan Chase & Co. 3,173,036(L) | 1001(L) | HKD 78.4477 | 88.957.269(L) 5.16(L)02/01/2026 | | | | | | 10,589,119(S) 0.61(S) | | | | | | 69,463,021(P) 4.03(P) | 格隆汇1月9日丨根据联交所最新权益披露资料显示，2026年1月2日，信达生物(01801.H ...